{"id":"W3212509840","doi":"10.1182/blood-2021-149478","title":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Internal medicine; CD22; Calicheamicin; Interim analysis; Minimal residual disease; Surgery; Hematopoietic stem cell transplantation; Chemotherapy; Gastroenterology; Transplantation; Oncology; Bone marrow; Randomized controlled trial; Lymphoma; CD20","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001983451,0.0004538278,0.002407236,0.0002385797,0.0001243735,0.00003359808,0.0003546058,0.0004964716,0.0002155471],"category_scores_gemma":[0.01331948,0.0003672898,0.0006910271,0.0004441139,0.0003533761,0.0001098352,0.0002090797,0.0005714159,0.00002248125],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005562584,"about_ca_system_score_gemma":0.003145955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002188615,"about_ca_topic_score_gemma":0.0001535342,"domain_scores_codex":[0.9942943,0.001147717,0.001968446,0.001004013,0.0008456063,0.0007398473],"domain_scores_gemma":[0.9891955,0.007898258,0.0008951082,0.001080881,0.0005032409,0.0004270132],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9309739,0.0320846,0.00002131996,0.00009964695,0.002404073,0.000656266,0.0005196821,0.000004441303,0.01000775,0.0001432062,0.002457378,0.02062773],"study_design_scores_gemma":[0.9336452,0.01496361,0.00004698901,0.0002027395,0.002831957,0.00006381135,0.00007042009,0.0008569045,0.04129633,0.0003551715,0.005364632,0.0003021761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8154727,0.00004899528,0.004559587,0.0009713187,0.0002668177,0.1745832,0.003418955,0.0001292763,0.0005491354],"genre_scores_gemma":[0.8000063,0.0002057825,0.03112692,0.0006645243,0.003319388,0.1574448,0.006516801,0.0002045515,0.0005109067],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03128858,"threshold_uncertainty_score":0.9998779,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01948813220071422,"score_gpt":0.3483837757388616,"score_spread":0.3288956435381474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}